Bhatt, Shivani http://orcid.org/0000-0003-3494-7246
Hillmer, Ansel T.
Girgenti, Matthew J. http://orcid.org/0000-0003-1647-326X
Rusowicz, Aleksandra http://orcid.org/0000-0002-8873-9875
Kapinos, Michael
Nabulsi, Nabeel http://orcid.org/0000-0001-8129-0051
Huang, Yiyun
Matuskey, David http://orcid.org/0000-0001-7508-6572
Angarita, Gustavo A.
Esterlis, Irina
Davis, Margaret T.
Southwick, Steven M.
Friedman, Matthew J. http://orcid.org/0000-0002-0497-6890
Girgenti, Matthew J.
Friedman, Matthew J.
Duman, Ronald S.
Krystal, John H.
Duman, Ronald S. http://orcid.org/0000-0001-8690-8439
Carson, Richard E. http://orcid.org/0000-0002-9338-7966
Krystal, John H.
Pietrzak, Robert H.
Cosgrove, Kelly P. http://orcid.org/0000-0003-1351-9576
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH110674, F30MH116607)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Gustavus and Louise Pfeiffer Research Foundation
VA National Center for PTSD
Article History
Received: 3 October 2019
Accepted: 31 March 2020
First Online: 12 May 2020
Competing interests
: Dr. John Krystal acknowledges the following relevant financial interests. He has a patent for glutamate modulator, riluzole, in augmentative treatment of anxiety disorders that was licensed by Biohaven Medical Sciences. His annual income from consultation for any of several pharmaceutical companies is not expected to exceed $10,000 in 2019. He holds stock in Biohaven Pharmaceuticals, Sage Pharmaceuticals, and Spring Care. He also receives over $10,000 from Society of Biological Psychiatry for his services as editor of the journal, Biological Psychiatry. The remaining authors declare no competing interests.